A review on current status of antiviral siRNA

Reviews in Medical Virology

Volumn 28, Issue 4, 2018, Pages

  Qureshi, Abid ^a   Tantray, Vaqar Gani ^a   Kirmani, Altaf Rehman ^a   Ahangar, Abdul Ghani ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

antiviral; clinical trials; delivery; design; limitations; resources; RNAi; siRNA; virus

Indexed keywords

SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARENAVIRIDAE; BUNYAVIRALES; CORONAVIRIDAE; FLAVIVIRIDAE; HEPADNAVIRIDAE; HEPEVIRIDAE; HERPESVIRIDAE; NONHUMAN; ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE; PARAMYXOVIRIDAE; PICORNAVIRIDAE; POLYOMAVIRIDAE; POXVIRIDAE; REOVIRIDAE; RETROVIRIDAE; REVIEW; RHABDOVIRIDAE; RNA INTERFERENCE; RNA VIRUS; TOGAVIRIDAE; ANIMAL; BIOLOGY; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; PROCEDURES; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGY; VIRUS; VIRUS GENOME; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENOME, VIRAL; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUSES;

EID: 85045414176     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1976     Document Type: Review

References (160)

1. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet. 2008;9:267-276. https://doi.org/10.1038/nrg2323
2. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates. J Virol. 2010;84:9733-9748. https://doi.org/10.1128/JVI.00694-10
3. Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 2006;13:532-540. https://doi.org/10.1038/sj.gt.3302645
4. Haasnoot J, Berkhout B. Nucleic acids-based therapeutics in the battle against pathogenic viruses. Handb Exp Pharmacol. 2009;243-263. https://doi.org/10.1007/978-3-540-79086-0_9
5. Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell. 2005;122:17-20. https://doi.org/10.1016/j.cell.2005.06.023
6. Woessmann W, Damm-Welk C, Fuchs U, Borkhardt A. RNA interference: new mechanisms for targeted treatment? Rev Clin Exp Hematol. 2003;7:270-291
7. Monga I, Qureshi A, Thakur N, Gupta AK, Kumar M. ASPsiRNA: a resource of ASP-siRNAs having therapeutic potential for human genetic disorders and algorithm for prediction of their inhibitory efficacy. G3 (Bethesda). 2017;7:2931-2943. https://doi.org/10.1534/g3.117.044024
8. Thakur A, Qureshi A, Kumar M. vhfRNAi: a web-platform for analysis of host genes involved in viral infections discovered by genome wide RNAi screens. Mol Biosyst. 2017;13:1377-1387. https://doi.org/10.1039/c6mb00841k
9. Singh SK. RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther. 2008;8:449-461. https://doi.org/10.1517/14712598.8.4.449
10. Rossi JJ. RNAi as a treatment for HIV-1 infection. Biotechniques. 2006. Suppl: 25-29
11. Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A. 2003;100:2718-2723. https://doi.org/10.1073/pnas.0437841100
12. Nakazawa M, Kadowaki SE, Watanabe I, Kadowaki Y, Takei M, Fukuda H. PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res. 2008;78:194-201. https://doi.org/10.1016/j.antiviral.2007.12.010
13. Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology. 2003;38:842-850. https://doi.org/10.1053/jhep.2003.50416
14. Shi Y, Yang DH, Xiong J, Jia J, Huang B, Jin YX. Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. Cell Res. 2005;15:193-200. https://doi.org/10.1038/sj.cr.7290286
15. Meng B, Lui YW, Meng S, Cao C, Hu Y. Identification of effective siRNA blocking the expression of SARS viral envelope E and RDRP genes. Mol Biotechnol. 2006;33:141-148. https://doi.org/10.1385/MB:33:2:141
16. Bousarghin L, Touze A, Gaud G, et al. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther. 2009;8:357-365. https://doi.org/10.1158/1535-7163.MCT-08-0626
17. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med. 2006;3:e96. https://doi.org/10.1371/journal.pmed.0030096
18. Chen Y, Mahato RI. siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target. 2008;16:140-148. https://doi.org/10.1080/10611860701878750
19. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther. 2008;16:557-564. https://doi.org/10.1038/sj.mt.6300382
20. Shah PS, Schaffer DV. Antiviral RNAi: translating science towards therapeutic success. Pharm Res. 2011;28:2966-2982. https://doi.org/10.1007/s11095-011-0549-8
21. Zhong P, Agosto LM, Munro JB, Mothes W. Cell-to-cell transmission of viruses. Curr Opin Virol. 2013;3:44-50. https://doi.org/10.1016/j.coviro.2012.11.004
22. Baker TS, Olson NH, Fuller SD. Adding the third dimension to virus life cycles: three-dimensional reconstruction of icosahedral viruses from cryo-electron micrographs. Microbiol Mol Biol Rev. 1999;63:862-922. table of contents
23. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19:17-25. https://doi.org/10.3350/cmh.2013.19.1.17
24. Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys. 2013;42:217-239. https://doi.org/10.1146/annurev-biophys-083012-130404
25. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811. https://doi.org/10.1038/35888
26. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519-1524. https://doi.org/10.1126/science.1111444
27. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553. https://doi.org/10.1126/science.1068999
28. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17:118-126. https://doi.org/10.1016/j.tcb.2006.12.007
29. Kawasaki H, Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser (Oxf). 2004;211-212. https://doi.org/10.1093/nass/48.1.211
30. Couzin J. Breakthrough of the year. Small RNAs make big splash. Science. 2002;298:2296-2297. https://doi.org/10.1126/science.298.5602.2296
31. Gitlin L, Andino R. Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol. 2003;77:7159-7165
32. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature. 2002;418:430-434. https://doi.org/10.1038/nature00873
33. Lecellier CH, Dunoyer P, Arar K, et al. A cellular microRNA mediates antiviral defense in human cells. Science. 2005;308:557-560. https://doi.org/10.1126/science.1108784
34. Lippman Z, Martienssen R. The role of RNA interference in heterochromatic silencing. Nature. 2004;431:364-370. https://doi.org/10.1038/nature02875
35. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol. 2008;111:356-364. https://doi.org/10.1016/j.ygyno.2008.06.033
36. Kuner R, Vogt M, Sultmann H, et al. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med (Berl). 2007;85:1253-1262. https://doi.org/10.1007/s00109-007-0230-1
37. Hoque KM, Azim MF, Mia MR, et al. Design of potential siRNA molecules for T antigen gene silencing of Merkel cell polyomavirus. Bioinformation. 2012;8:924-930. https://doi.org/10.6026/97320630008924
38. Sabbioni S, Callegari E, Spizzo R, et al. Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag. Cancer Gene Ther. 2007;14:297-305. https://doi.org/10.1038/sj.cgt.7701014
39. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006;348:489-497. https://doi.org/10.1016/jvirol200601.013
40. Vigne S, Duraffour S, Andrei G, Snoeck R, Garin D, Crance JM. Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrob Agents Chemother. 2009;53:2579-2588. https://doi.org/10.1128/AAC.01626-08
41. Vigne S, Germi R, Duraffour S, et al. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Antivir Ther. 2008;13:357-368
42. He Y, Jiang Y, Wang G, et al. Inhibition of HBV-DNA replication and expression by siRNA based on magnetic nanoparticles transferring in HepG2 2.2.15 cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:543-548. https://doi.org/10.3969/j.issn.1672-7347.2010.06.002
43. Jenke AC, Wilhelm AD, Orth V, Lipps HJ, Protzer U, Wirth S. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. Antimicrob Agents Chemother. 2008;52:2355-2359. https://doi.org/10.1128/AAC.00067-08
44. Wang J, Feng SS, Wang S, Chen ZY. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm. 2010;400:194-200. S0378-5173(10)00656-3. https://doi.org/10.1016/j.ijpharm.2010.08.026
45. Oh ST, Kim M, Lee SK. Maintenance of the viral episome is essential for the cell survival of an Epstein-Barr virus positive gastric carcinoma cell line. Arch Pharm Res. 2009;32:729-736. https://doi.org/10.1007/s12272-009-1512-7
46. Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S. The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro. J Virol. 2005;79:11914-11924. https://doi.org/10.1128/JVI791811914-11924.2005
47. Yoon JS, Kim SH, Shin MC, et al. Inhibition of herpesvirus-6B RNA replication by short interference RNAs. J Biochem Mol Biol. 2004;37:383-385
48. Kobayashi T, Chappell JD, Danthi P, Dermody TS. Gene-specific inhibition of reovirus replication by RNA interference. J Virol. 2006;80:9053-9063. https://doi.org/10.1128/JVI.00276-06
49. Lopez T, Rojas M, Ayala-Breton C, Lopez S, Arias CF. Reduced expression of the rotavirus NSP5 gene has a pleiotropic effect on virus replication. J Gen Virol. 2005;86:1609-1617. https://doi.org/10.1099/Vir0.80827-80820
50. Sanchez AB, Perez M, Cornu T, de la Torre JC. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol. 2005;79:11071-11081. https://doi.org/10.1128/JVI791711071-11081.2005
51. Muller S, Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother. 2007;51:2215-2218. https://doi.org/10.1128/AAC.01368-06
52. Artuso MC, Ellenberg PC, Scolaro LA, Damonte EB, Garcia CC. Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res. 2009;84:31-37. https://doi.org/10.1016/j.antiviral.2009.07.001
53. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005;11:56-62. https://doi.org/10.1038/nm1174
54. Otaki M, Sada K, Kadoya H, Nagano-Fujii M, Hotta H. Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Res. 2006;70:105-111. https://doi.org/10.1016/j.antiviral.2006.01.009
55. Deffrasnes C, Cavanagh MH, Goyette N, et al. Inhibition of human metapneumovirus replication by small interfering RNA. Antivir Ther. 2008;13:821-832
56. Meshram CD, Singh NK, Sonwane AA, et al. Evaluation of single and dual siRNAs targeting rabies virus glycoprotein and nucleoprotein genes for inhibition of virus multiplication in vitro. Arch Virol. 2013;158:2323-2332. https://doi.org/10.1007/s00705-013-1738-z
57. Brandao PE, Castilho JG, Fahl W, et al. Short-interfering RNAs as antivirals against rabies. Braz J Infect Dis. 2007;11:224-225
58. Sonwane AA, Dahiya SS, Saini M, Chaturvedi VK, Singh RP, Gupta PK. Inhibition of rabies virus multiplication by siRNA delivered through adenoviral vector in vitro in BHK-21 cells and in vivo in mice. Res Vet Sci. 2012;93:498-503. https://doi.org/10.1016/j.rvsc.2011.06.008
59. Flusin O, Vigne S, Peyrefitte CN, Bouloy M, Crance JM, Iseni F. Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Virol J. 2011;8:249. https://doi.org/10.1186/1743-422X-8-249
60. Soldan SS, Plassmeyer ML, Matukonis MK, Gonzalez-Scarano F. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. J Virol. 2005;79:234-244. https://doi.org/10.1128/JVI791234-244.2005
61. Radhakrishnan S, Gordon J, Del Valle L, Cui J, Khalili K. Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol. 2004;78:7264-7269. https://doi.org/10.1128/JVI.78.13.7264-7269.2004
62. Groseth A, Hoenen T, Alimonti JB, et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis. 2007;196. Suppl 2: S382-389. https://doi.org/10.1086/520604
63. Fowler T, Bamberg S, Moller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol. 2005;86:1181-1188. https://doi.org/10.1099/Vir0.80622-80620
64. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 2015;521:362-365. https://doi.org/10.1038/nature14442
65. Zhou H, Jin M, Yu Z, et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res. 2007;76:186-193. https://doi.org/10.1016/jantiviral200707.002
66. Suzuki H, Saitoh H, Suzuki T, Takaku H. Baculovirus-mediated bispecific short-hairpin small-interfering RNAs have remarkable ability to cope with both influenza viruses A and B. Oligonucleotides. 2009;19:307-316. https://doi.org/10.1089/oli.2009.0189
67. Cheng C, Yao L, Chen A, et al. Inhibitory effect of small interfering RNA specific for a novel candidate target in PB1 gene of influenza A virus. J Drug Target. 2009;17:133-139. https://doi.org/10.1080/10611860802473048
68. Tan EL, Tan TM, Tak Kwong Chow V, Poh CL. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;15:1931-1938. https://doi.org/10.1038/sj.mt.6300287
69. Lu WW, Hsu YY, Yang JY, Kung SH. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem Biophys Res Commun. 2004;325:494-499. https://doi.org/10.1016/j.bbrc.2004.10.062
70. Saulnier A, Pelletier I, Labadie K, Colbere-Garapin F. Complete cure of persistent virus infections by antiviral siRNAs. Mol Ther. 2006;13:142-150. https://doi.org/10.1016/j.ymthe.2005.07.697
71. Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun. 2008;376:718-722. https://doi.org/10.1016/j.bbrc.2008.09.040
72. Siu RW, Fragkoudis R, Simmonds P, et al. Antiviral RNA interference responses induced by Semliki Forest virus infection of mosquito cells: characterization, origin, and frequency-dependent functions of virus-derived small interfering RNAs. J Virol. 2011;85:2907-2917. https://doi.org/10.1128/JVI.02052-10
73. Zhang Y, Li T, Fu L, et al. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett. 2004;560:141-146. https://doi.org/10.1016/S0014-5793(04)00087-0
74. Wang Z, Ren L, Zhao X, et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol. 2004;78:7523-7527. https://doi.org/10.1128/JVI.78.14.7523-7527.2004
75. Subramanya S, Kim SS, Abraham S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol. 2010;84:2490-2501. https://doi.org/10.1128/JVI.02105-08
76. Ye C, Abraham S, Wu H, Shankar P, Manjunath N. Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One. 2011;6:e17889. https://doi.org/10.1371/journal.pone.0017889
77. Bai F, Wang T, Pal U, Bao F, Gould LH, Fikrig E. Use of RNA interference to prevent lethal murine West Nile virus infection. J Infect Dis. 2005;191:1148-1154. https://doi.org/10.1086/428507
78. Kumar A, Panda SK, Durgapal H, Acharya SK, Rehman S, Kar UK. Inhibition of hepatitis E virus replication using short hairpin RNA (shRNA). Antiviral Res. 2010;85:541-550. https://doi.org/10.1016/j.antiviral.2010.01.005
79. Huang F, Hua X, Yang S, Yuan C, Zhang W. Effective inhibition of hepatitis E virus replication in A549 cells and piglets by RNA interference (RNAi) targeting RNA-dependent RNA polymerase. Antiviral Res. 2009;83:274-281. https://doi.org/10.1016/j.antiviral.2009.06.008
80. Huang F, Zhou J, Yang Z, et al. RNA interference inhibits hepatitis E virus mRNA accumulation and protein synthesis in vitro. Vet Microbiol. 2010;142:261-267. https://doi.org/10.1016/jvetmic200910.023
81. Naito Y, Nohtomi K, Onogi T, et al. Optimal design and validation of antiviral siRNA for targeting HIV-1. Retrovirology. 2007;4:80. https://doi.org/10.1186/1742-4690-4-80
82. Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for treatment of HIV-1 infection. Genome Med. 2015;7:50. https://doi.org/10.1186/s13073-015-0174-y174
83. Liu C, Liang Z, Kong X. Efficacy analysis of combinatorial siRNAs against HIV derived from one double hairpin RNA precursor. Front Microbiol. 2017;8:1651. https://doi.org/10.3389/fmicb.2017.01651
84. Chang LJ, Liu X, He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther. 2005;12:1133-1144. https://doi.org/10.1038/sj.gt.3302509
85. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27. https://doi.org/10.1016/j.virol.2004.03.033
86. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003;22:5938-5945. https://doi.org/10.1038/sj.onc.1206894
87. Chang JT, Kuo TF, Chen YJ, et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther. 2010;17:827-836. https://doi.org/10.1038/cgt2010.38
88. Johne R, Buck CB, Allander T, et al. Taxonomical developments in the family Polyomaviridae. Arch Virol. 2011;156:1627-1634. https://doi.org/10.1007/s00705-011-1008-x
89. Bahar MW, Graham SC, Stuart DI, Grimes JM. Insights into the evolution of a complex virus from the crystal structure of vaccinia virus D13. Structure. 2011;19:1011-1020. https://doi.org/10.1016/j.str.2011.03.023
90. Lantermann M, Schwantes A, Sliva K, Sutter G, Schnierle BS. Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. Virus Res. 2007;126:1-8. https://doi.org/10.1016/j.virusres.2007.01.009
91. Robertson BH, Margolis HS. Primate hepatitis B viruses—genetic diversity, geography and evolution. Rev Med Virol. 2002;12:133-141. https://doi.org/10.1002/rmv.348
92. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003;8:769-776
93. Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology. 2006;346:385-393. https://doi.org/10.1016/j.virol.2005.11.021
94. Bhuyan PK, Kariko K, Capodici J, et al. Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J Virol. 2004;78:10276-10281. https://doi.org/10.1128/JVI.78.19.10276-10281.2004
95. Anon MC, Grau O, Segovia ZM, Franzefernandez MT. RNA composition of Junin virus. J Virol. 1976;18:833-838
96. Franke J, Essbauer S, Ahne W, Blahak S. Identification and molecular characterization of 18 paramyxoviruses isolated from snakes. Virus Res. 2001;80:67-74
97. Zhang W, Tripp RA. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol. 2008;82:12221-12231. https://doi.org/10.1128/JVI.01557-08
98. Elliott RM. Emerging viruses: the Bunyaviridae. Mol Med. 1997;3:572-577
99. Matoba T, Orba Y, Suzuki T, et al. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Neuropathology. 2008;28:286-294. https://doi.org/10.1111/j.1440-1789.2007.00878.x
100. Kiley MP, Bowen ET, Eddy GA, et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology. 1982;18:24-32
101. Ge Q, Eisen HN, Chen J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res. 2004;102:37-42. https://doi.org/10.1016/j.virusres.2004.01.013
102. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004;101:8676-8681. https://doi.org/10.1073/pnas.0402486101
103. Santti J, Vainionpaa R, Hyypia T. Molecular detection and typing of human picornaviruses. Virus Res. 1999;62:177-183
104. Ahn J, Jun ES, Lee HS, et al. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. 2005;79:8620-8624. https://doi.org/10.1128/JVI79138620-8624.2005
105. Sidwell RW, Smee DF. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res. 2003;57:101-111
106. Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 2005;65:45-48. https://doi.org/10.1016/j.antiviral.2004.09.005
107. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11:944-951. https://doi.org/10.1038/nm1280
108. Paula T, Pablo R, Eugenia V, et al. New drug targets for hepatitis C and other Flaviviridae viruses. Infect Disord Drug Targets. 2009;9:133-147
109. Seo MY, Abrignani S, Houghton M, Han JH. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol. 2003;77:810-812
110. Anthony KG, Bai F, Krishnan MN, Fikrig E, Koski RA. Effective siRNA targeting of the 3′ untranslated region of the West Nile virus genome. Antiviral Res. 2009;82:166-168. https://doi.org/10.1016/j.antiviral.2008.12.007
111. Stein DA, Perry ST, Buck MD, et al. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol. 2011;85:10154-10166. https://doi.org/10.1128/JVI.05298-11
112. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet. 2017;390:2099-2109. https://doi.org/10.1016/S0140-6736(17)31450-2
113. Hashem M, Shuvo MA. A computational approach to design potential antiviral RNA for 3'UTR post transcriptional gene silencing of different strains of Zika virus. J Young Pharm. 2017;9
114. Gupta AK, Kaur K, Rajput A, et al. ZikaVR: an integrated Zika virus resource for genomics, proteomics, phylogenetic and therapeutic analysis. Sci Rep. 2016;6:32713. https://doi.org/10.1038/srep32713
115. Savidis G, McDougall WM, Meraner P, et al. Identification of Zika virus and dengue virus dependency factors using functional genomics. Cell Rep. 2016;16:232-246. https://doi.org/10.1016/jcelrep201606.028
116. Kim FJ, Battini JL, Manel N, Sitbon M. Emergence of vertebrate retroviruses and envelope capture. Virology. 2004;318:183-191. https://doi.org/10.1016/j.virol.2003.09.026
117. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;8:681-686. https://doi.org/10.1038/nm725
118. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800-8805. https://doi.org/10.1073/pnas.0912186107
119. Gish RG, Satishchandran C, Young M, Pachuk C. RNA interference and its potential applications to chronic HBV treatment: results of a phase I safety and tolerability study. Antivir Ther. 2011;16:547-554. https://doi.org/10.3851/IMP1798
120. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014;42:609-621. https://doi.org/10.1093/nar/gkt852
121. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-340. https://doi.org/10.1038/nrg2968
122. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013;27:565-583. https://doi.org/10.1007/s40259-013-0046-1
123. Lambeth LS, Zhao Y, Smith LP, Kgosana L, Nair V. Targeting Marek's disease virus by RNA interference delivered from a herpesvirus vaccine. Vaccine. 2009;27:298-306. https://doi.org/10.1016/j.vaccine.2008.10.023
124. Chen W, Liu M, Jiao Y, et al. Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J Virol. 2006;80:3559-3566. https://doi.org/10.1128/JVI8073559-3566.2006
125. Keene KM, Foy BD, Sanchez-Vargas I, Beaty BJ, Blair CD, Olson KE. RNA interference acts as a natural antiviral response to O'nyong-nyong virus (Alphavirus; Togaviridae) infection of Anopheles gambiae. Proc Natl Acad Sci U S A. 2004;101:17240-17245. https://doi.org/10.1073/pnas.0406983101
126. Umbach JL, Cullen BR. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev. 2009;23:1151-1164. https://doi.org/10.1101/gad.1793309
127. Kurreck J. siRNA efficiency: structure or sequence-that is the question. J Biomed Biotechnol. 2006; 2006;83757. https://doi.org/10.1155/JBB/2006/83757
128. Wang X, Varma RK, Beauchamp L, Magdaleno S, Sendera TJ. Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res. 2009;37:e152. https://doi.org/10.1093/nar/gkp864
129. Lee HS, Ahn J, Jee Y, et al. Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region. J Gen Virol. 2007;88:2003-2012. https://doi.org/10.1099/Vir0.82633-82630
130. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA. 2006;12:1197-1205. https://doi.org/10.1261/rna.30706
131. Kenski DM, Butora G, Willingham AT, et al. siRNA-optimized modifications for enhanced in vivo activity. Mol Ther Nucleic Acids. 2012;1:e5. https://doi.org/10.1038/mtna.2011.4
132. Dar SA, Thakur A, Qureshi A, Kumar M. siRNAmod: a database of experimentally validated chemically modified siRNAs. Sci Rep. 2016;6:20031. https://doi.org/10.1038/srep20031
133. Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41:1349-1356. https://doi.org/10.1002/hep.20702
134. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492-503. https://doi.org/10.1208/s12248-010-9210-4
135. Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel). 2017;7. https://doi.org/10.3390/nano7040077
136. Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv. 2008;5:1301-1311. https://doi.org/10.1517/17425240802568505
137. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002-1007. https://doi.org/10.1038/nbt1122
138. Khurana B, Goyal AK, Budhiraja A, Aora D, Vyas SP. Lipoplexes versus nanoparticles: pDNA/siRNA delivery. Drug Deliv. 2013;20:57-64. https://doi.org/10.3109/10717544.2012.752419
139. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12:967-977. https://doi.org/10.1038/nmat3765
140. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-138. https://doi.org/10.1038/nrd2742
141. Lu PY, Woodle MC. Delivering small interfering RNA for novel therapeutics. Methods Mol Biol. 2008;437:93-107. https://doi.org/10.1007/978-1-59745-210-6_3
142. Thakur N, Qureshi A, Kumar M. VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res. 2012;40:D230-D236. https://doi.org/10.1093/nar/gkr1147
143. Tyagi A, Ahmed F, Thakur N, Sharma A, Raghava GP, Kumar M. HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One. 2011;6:e25917. https://doi.org/10.1371/journal.pone.0025917
144. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498. https://doi.org/10.1038/35078107
145. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326-330. https://doi.org/10.1038/nbt936
146. Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004;32:936-948. https://doi.org/10.1093/nar/gkh247
147. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun. 2004;316:1050-1058. https://doi.org/10.1016/j.bbrc.2004.02.157
148. Jagla B, Aulner N, Kelly PD, et al. Sequence characteristics of functional siRNAs. RNA. 2005;11:864-872. https://doi.org/10.1261/rna.7275905
149. Naito Y, Ui-Tei K, Nishikawa T, Takebe Y, Saigo K. siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res. 2006;34:W448-450. https://doi.org/10.1093/nar/gkl214
150. Saetrom P. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. Bioinformatics. 2004;20:3055-3063. https://doi.org/10.1093/bioinformatics/bth364
151. Huesken D, Lange J, Mickanin C, et al. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol. 2005;23:995-1001. https://doi.org/10.1038/nbt1118
152. Peek AS. Improving model predictions for RNA interference activities that use support vector machine regression by combining and filtering features. BMC Bioinformatics. 2007;8:182. https://doi.org/10.1186/1471-2105-8-182
153. Qureshi A, Thakur N, Kumar M. VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. J Transl Med. 2013;11:305. https://doi.org/10.1186/1479-5876-11-305
154. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest. 2011;41:221-232. https://doi.org/10.1111/j.1365-2362.2010.02400.x
155. Thakur A, Fitzpatrick S, Zaman A, et al. Strategies for ocular siRNA delivery: potential and limitations of non-viral nanocarriers. J Biol Eng. 2012;6:7. https://doi.org/10.1186/1754-1611-6-7
156. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol. 2007;76:9-21. https://doi.org/10.1007/s00253-007-0984-y
157. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9:1034-1048
158. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther. 2006;14:463-470. https://doi.org/10.1016/j.ymthe.2006.06.001
159. Wang S, Shi Z, Liu W, Jules J, Feng X. Development and validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing. BMC Biotechnol. 2006;6:50. https://doi.org/10.1186/1472-6750-6-50
160. Sachidanandam R. RNAi as a bioinformatics consumer. Brief Bioinform. 2005;6:146-162